Knowledge Center

Topic
Close
Clear
13.04.2021

When and why should my API be a new crystalline polymorph, amorphous, a co-crystal, or an alternative salt?

When and why should my API be a new crystalline polymorph, amorphous, a co-crystal, or an alternative salt?
Maytal Piran
17.08.2020

Teva api Adopts New Nitrosamine Regulations

Teva api Adopts New Nitrosamine Regulations
Olga Pogrebinsky
10.08.2020

Navigating China’s API Regulations

Navigating China’s API Regulations
Olga Pogrebinsky
24.06.2020

Creatively using co-crystals to produce alternative generic products

Creatively using co-crystals to produce alternative generic products
Maytal Piran
31.10.2019

Teva api Offers New API Sterilization Services

Teva api Offers New API Sterilization Services
11.09.2019

EcoVadis assessment

EcoVadis assessment
07.04.2019

A global API supplier that understands the API industry!

A global API supplier that understands the API industry!
29.01.2019

Trends in the API industry that you should be aware of (2019)

Trends in the API industry that you should be aware of (2019)
Jordan Rudner
04.11.2018

Why changes in the API manufacturing landscape is great news for Teva api

Why changes in the API manufacturing landscape is great news for Teva api
View more articles

Last site inspections

  • Feb 17-21, 2020 Teva API had a successful inspection in the Teva api Italy, Rho site by AIFA
  • Feb 11-14, 2020 Teva API had a successful inspection in the Teva api India, Malanpur site by PMDA
  • Jan 20-24, 2020 Teva API had a successful inspection in the Teva api Croatia site by USFDA
View all Site Inspections

Last regulatory updates

  • Nov 01, 2021 New CA DMF for is available.
  • Sep 13, 2021 CEP
  • Jun 13, 2021 CEP
View all Regulatory Updates